Sequencing Systemic Therapies for Metastatic Kidney Cancer

Parminder - Singh, Neeraj Agarwal, Sumanta K. Pal

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Abstract: Defining the appropriate sequencing of therapies for metastatic renal cell carcinoma (mRCC) has become increasingly complex in recent years given the approval of multiple targeted therapies. These targeted therapies fall into 2 broad mechanistic categories: (1) inhibitors of the mammalian target of rapamycin (mTOR), and (2) vascular endothelial growth factor (VEGF)-directed agents. In the current manuscript, data from relevant trials are reviewed to provide a context in which to use these agents across the first- and second-line setting. Strategies to incorporate promising agents currently in late stage development for mRCC are also described.

Opinion statement: Currently, there is no consensus as to the optimal sequence of therapies for patients with metastatic renal cell carcinoma (mRCC). While interleukin-2 (IL-2) and temsirolimus are potential considerations for selected patients in the first-line setting, the majority of patients in this setting are likely candidates for vascular endothelial growth factor (VEGF)-directed therapies. Specifically, these therapies include sunitinib, pazopanib, and bevacizumab/interferon-α. Using the comparative data discussed herein, the relative merits of each should be discussed. In the second-line setting (following VEGF-directed therapy), axitinib, and everolimus are supported by phase III data. There is no data directly comparing the 2 agents—however, studies reviewed in the current manuscript (comparing VEGF- and mammalian target of rapamycin [mTOR]-directed approaches in the second-line setting) can potentially be used to inform clinical decision making.

Original languageEnglish (US)
JournalCurrent Treatment Options in Oncology
Volume16
Issue number1
DOIs
StatePublished - 2015

Fingerprint

Kidney Neoplasms
Vascular Endothelial Growth Factor A
Renal Cell Carcinoma
Manuscripts
Sirolimus
Therapeutics
Interferons
Interleukin-2

Keywords

  • Cabozantinib
  • mTOR
  • Nivolumab
  • Renal cell carcinoma
  • Sequencing
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Sequencing Systemic Therapies for Metastatic Kidney Cancer. / Singh, Parminder -; Agarwal, Neeraj; Pal, Sumanta K.

In: Current Treatment Options in Oncology, Vol. 16, No. 1, 2015.

Research output: Contribution to journalArticle

@article{fa291d3afab9439d9e27820dea70e4db,
title = "Sequencing Systemic Therapies for Metastatic Kidney Cancer",
abstract = "Abstract: Defining the appropriate sequencing of therapies for metastatic renal cell carcinoma (mRCC) has become increasingly complex in recent years given the approval of multiple targeted therapies. These targeted therapies fall into 2 broad mechanistic categories: (1) inhibitors of the mammalian target of rapamycin (mTOR), and (2) vascular endothelial growth factor (VEGF)-directed agents. In the current manuscript, data from relevant trials are reviewed to provide a context in which to use these agents across the first- and second-line setting. Strategies to incorporate promising agents currently in late stage development for mRCC are also described.Opinion statement: Currently, there is no consensus as to the optimal sequence of therapies for patients with metastatic renal cell carcinoma (mRCC). While interleukin-2 (IL-2) and temsirolimus are potential considerations for selected patients in the first-line setting, the majority of patients in this setting are likely candidates for vascular endothelial growth factor (VEGF)-directed therapies. Specifically, these therapies include sunitinib, pazopanib, and bevacizumab/interferon-α. Using the comparative data discussed herein, the relative merits of each should be discussed. In the second-line setting (following VEGF-directed therapy), axitinib, and everolimus are supported by phase III data. There is no data directly comparing the 2 agents—however, studies reviewed in the current manuscript (comparing VEGF- and mammalian target of rapamycin [mTOR]-directed approaches in the second-line setting) can potentially be used to inform clinical decision making.",
keywords = "Cabozantinib, mTOR, Nivolumab, Renal cell carcinoma, Sequencing, VEGF",
author = "Singh, {Parminder -} and Neeraj Agarwal and Pal, {Sumanta K.}",
year = "2015",
doi = "10.1007/s11864-014-0316-2",
language = "English (US)",
volume = "16",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Sequencing Systemic Therapies for Metastatic Kidney Cancer

AU - Singh, Parminder -

AU - Agarwal, Neeraj

AU - Pal, Sumanta K.

PY - 2015

Y1 - 2015

N2 - Abstract: Defining the appropriate sequencing of therapies for metastatic renal cell carcinoma (mRCC) has become increasingly complex in recent years given the approval of multiple targeted therapies. These targeted therapies fall into 2 broad mechanistic categories: (1) inhibitors of the mammalian target of rapamycin (mTOR), and (2) vascular endothelial growth factor (VEGF)-directed agents. In the current manuscript, data from relevant trials are reviewed to provide a context in which to use these agents across the first- and second-line setting. Strategies to incorporate promising agents currently in late stage development for mRCC are also described.Opinion statement: Currently, there is no consensus as to the optimal sequence of therapies for patients with metastatic renal cell carcinoma (mRCC). While interleukin-2 (IL-2) and temsirolimus are potential considerations for selected patients in the first-line setting, the majority of patients in this setting are likely candidates for vascular endothelial growth factor (VEGF)-directed therapies. Specifically, these therapies include sunitinib, pazopanib, and bevacizumab/interferon-α. Using the comparative data discussed herein, the relative merits of each should be discussed. In the second-line setting (following VEGF-directed therapy), axitinib, and everolimus are supported by phase III data. There is no data directly comparing the 2 agents—however, studies reviewed in the current manuscript (comparing VEGF- and mammalian target of rapamycin [mTOR]-directed approaches in the second-line setting) can potentially be used to inform clinical decision making.

AB - Abstract: Defining the appropriate sequencing of therapies for metastatic renal cell carcinoma (mRCC) has become increasingly complex in recent years given the approval of multiple targeted therapies. These targeted therapies fall into 2 broad mechanistic categories: (1) inhibitors of the mammalian target of rapamycin (mTOR), and (2) vascular endothelial growth factor (VEGF)-directed agents. In the current manuscript, data from relevant trials are reviewed to provide a context in which to use these agents across the first- and second-line setting. Strategies to incorporate promising agents currently in late stage development for mRCC are also described.Opinion statement: Currently, there is no consensus as to the optimal sequence of therapies for patients with metastatic renal cell carcinoma (mRCC). While interleukin-2 (IL-2) and temsirolimus are potential considerations for selected patients in the first-line setting, the majority of patients in this setting are likely candidates for vascular endothelial growth factor (VEGF)-directed therapies. Specifically, these therapies include sunitinib, pazopanib, and bevacizumab/interferon-α. Using the comparative data discussed herein, the relative merits of each should be discussed. In the second-line setting (following VEGF-directed therapy), axitinib, and everolimus are supported by phase III data. There is no data directly comparing the 2 agents—however, studies reviewed in the current manuscript (comparing VEGF- and mammalian target of rapamycin [mTOR]-directed approaches in the second-line setting) can potentially be used to inform clinical decision making.

KW - Cabozantinib

KW - mTOR

KW - Nivolumab

KW - Renal cell carcinoma

KW - Sequencing

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84924365535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924365535&partnerID=8YFLogxK

U2 - 10.1007/s11864-014-0316-2

DO - 10.1007/s11864-014-0316-2

M3 - Article

VL - 16

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 1

ER -